Latest News-Deqi(Zhejiang)Pharmaceutical Technology Co. Ltd. Mediaroom_Page

Antengene Included in the MSCI Global Small Cap Indexes - MSCI China Index Constituent Stocks

SHANGHAI and HONG KONG, Nov. 26, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", S...

2021-11-26 11:34 3664

Treating Patients Beyond Borders - Antengene Successfully Hosted Its First R&D Day

- Highlighted R&D Strategy and Broad Pipeline of 15 Programs including 10 with Worldwide Rights -...

2021-11-19 13:00 2654

Treating Patients Beyond Borders - Antengene Successfully Hosted Its First R&D Day

Antengene Announces IND Approval in China for a Phase I/II Study of Selinexor (ATG-010) in Patients with Non-Hodgkin Lymphoma

SHANGHAI and Hong Kong, Nov. 19, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", S...

2021-11-19 08:30 2349

Antengene Presents Compelling Preclinical Data on Two Programs at the Society for Immunotherapy of Cancer (SITC) Annual Meeting on November 12, 2021

-ATG-101, a novel PD-L1/4-1BB bispecific antibody, shows potent in vivo anti-tumor efficacy in chec...

2021-11-15 08:25 2151

Antengene to Release Preliminary Results of Selinexor for the Treatment of Peripheral T-Cell Lymphoma and NK/T-Cell Lymphoma at the 2021 ASH Annual Meeting

SHANGHAI and HONG KONG, Nov. 9, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SE...

2021-11-09 16:30 2254

Antengene Granted IND Approval in China for the Phase Ib Study of ATG-008 (Onatasertib) in Combination with ATG-010 (Selinexor) in Patients with Diffuse Large B-Cell Lymphoma

SHANGHAI and HONG KONG, Nov. 2, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SE...

2021-11-02 08:30 2586

Antengene Receives FDA Approval of IND for Phase 1 Trial of ATG-101 (PD-L1/4-1BB bispecific antibody) in Solid Tumors and Non-Hodgkin Lymphoma

SHANGHAI and HONG KONG, Nov. 1, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SE...

2021-11-01 08:40 2455

Antengene to Host its First R&D Days on November 16 and November 18, 2021

* Virtual Event (in English) on November 16 * On Site Event with Live Webcast (in Mandarin) on N...

2021-10-25 20:00 2242

Antengene Enters into a Research Collaboration & License Option Agreement with LegoChem Biosciences for New Antibody-Drug Conjugate Candidates

SHANGHAI and HONG KONG, Oct. 21, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", S...

2021-10-21 16:00 2617

Antengene to Present Data of Its PD-L1/4-1BB Bispecific Antibody ATG-101 and ERK1/2 Inhibitor ATG-017 at SITC 2021

SHANGHAI and HONG KONG, Oct. 15, 2021 /PRNewswire/ -- The 36th Annual Meeting of the Society for Im...

2021-10-15 13:33 2041

Antengene Announces Approval of the Phase II Study of Selinexor for the Treatment of Myelofibrosis in China

SHANGHAI and HONG KONG, Aug. 24, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", S...

2021-08-24 08:30 2359

Antengene and MindRank AI Enter into Collaboration to Advance the Development of Difficult-to-Drug Molecular Targets

SHANGHAI and HONG KONG, Aug. 9, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SE...

2021-08-09 08:30 2643

Antengene Announces the Approval of First-in-Class Oral XPO1 Inhibitor Selinexor in South Korea for the Treatment of Relapsed or Refractory Multiple Myeloma and Diffuse Large B-Cell Lymphoma

SEOUL, South Korea and SHANGHAI and HONG KONG, Aug. 2, 2021 /PRNewswire/ -- Antengene Corporation L...

2021-08-02 07:29 5623

Antengene and Its Partners Publish Preclinical Data Demonstrating the Encouraging Activity of Selinexor in the Prevention and Treatment of SARS-CoV-2 Infections

SHANGHAI and HONG KONG, July 26, 2021 /PRNewswire/ -- In June 2021, results from a preclinical stud...

2021-07-26 08:44 2084

Antengene and Its Partners Publish Preclinical Data Demonstrating the Encouraging Activity of Selinexor in the Prevention and Treatment of SARS-CoV-2 Infections

Antengene Announces The Approval by Human Research Ethics Committee in Australia and to Start the Phase 1 Trial of ATG-101 (the first PD-L1/4-1BB bispecific antibody) in Solid Tumors and Non-Hodgkin Lymphoma

SHANGHAI and HONG KONG, July 22, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", S...

2021-07-22 09:27 2316

Antengene Submits New Drug Application for Selinexor in Taiwan for the Treatment of Three Indications in Hematologic Malignancies

SHANGHAI and HONG KONG, July 14, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", S...

2021-07-14 10:00 21190

Antengene Announces Acceptance of IND Application in China for the Phase II Clinical Trial of Single-Agent Selinexor for the Treatment of Myelofibrosis (MF)

SHANGHAI and HONG KONG, July 6, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SE...

2021-07-06 08:00 2696

Antengene Provides an Update on Its Latest Developments

* Announces two new in-house discovered assets - ATG-031, a potential first-in-class anti-CD24 mo...

2021-06-18 14:10 11537

Antengene's Partner Karyopharm Therapeutics Announces Updated Data of Eltanexor in Patients with Hypomethylating Agent Refractory MDS

--Of the 15 patients evaluable for efficacy, 7 (47%) had mCR and 5 (33%) had SD for a total disease...

2021-06-09 08:00 2632

Antengene Announces Publication of Abstract on XPO1 Inhibitor Selinexor in Relapsed or Refractory Multiple Myeloma at ASCO 2021 and EHA 2021

SHANGHAI and HONG KONG, June 4, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SE...

2021-06-04 08:00 2761